Aclaris Therapeutics Inc Asset Resilience Ratio

Latest as of September 2025: 40.25%

Aclaris Therapeutics Inc asset resilience ratio. Aclaris Therapeutics Inc (ACRS) has an Asset Resilience Ratio of 40.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Aclaris Therapeutics Inc (ACRS) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$70.66 Million

Cash + Short-term Investments

Total Assets

$175.53 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of Aclaris Therapeutics Inc (2013–2024)

Asset resilience ratio of Aclaris Therapeutics Inc from 2013 to 2024. This chart shows how Aclaris Therapeutics Inc's Asset Resilience Ratio has changed over time. Read ACRS current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Aclaris Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ACRS total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$70.66 Million	40.25%
Total Liquid Assets	$70.66 Million	40.25%

Asset Resilience Insights

Very High Liquidity: Aclaris Therapeutics Inc maintains exceptional liquid asset reserves at 40.25% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Aclaris Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Aclaris Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Aclaris Therapeutics Inc Asset Resilience Ratio by Year (2013–2024)

Aclaris Therapeutics Inc asset resilience ratio by year from 2013 to 2024. The table below shows the annual Asset Resilience Ratio data for Aclaris Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	40.41%	$89.02 Million	$220.33 Million	+0.27pp
2023-12-31	40.13%	$79.23 Million	$197.41 Million	-27.54pp
2022-12-31	67.67%	$172.29 Million	$254.60 Million	+2.36pp
2021-12-31	65.31%	$164.06 Million	$251.21 Million	+20.01pp
2020-12-31	45.30%	$32.07 Million	$70.78 Million	+5.55pp
2019-12-31	39.76%	$39.08 Million	$98.30 Million	-0.51pp
2018-12-31	40.26%	$110.95 Million	$275.57 Million	-31.05pp
2017-12-31	71.31%	$173.66 Million	$243.51 Million	+10.52pp
2016-12-31	60.80%	$107.05 Million	$176.09 Million	-18.95pp
2015-12-31	79.74%	$75.02 Million	$94.08 Million	+48.82pp
2014-12-31	30.92%	$5.37 Million	$17.38 Million	+4.62pp
2013-12-31	26.30%	$3.74 Million	$14.21 Million	--

pp = percentage points

About Aclaris Therapeutics Inc

NASDAQ:ACRS USA Biotechnology

Market Cap

$398.71 Million

Market Cap Rank

#13767 Global

#3333 in USA

Share Price

$3.68

Change (1 day)

-1.60%

52-Week Range

$2.13 - $6.54

All Time High

$32.99